Gedeon Richter’s Ryeqo (relugolix, estradiol, and norethindrone acetate) Receives NICE Recommendation for the Treatment of Women with Uterine Fibroids
Shots:
- NICE has issued final draft guidance recommending Ryeqo (40mg relugolix/1mg estradiol/0.5mg norethisterone acetate) for routine use in the NHS as a treatment option for heavy menstrual bleeding associated with UF
- The P-III (LIBERTY) program consists of 2 P-III studies evaluating Ryeqo vs PBO in adult women with UF. The results showed that ≥71% vs 19% of women treated with Ryeqo responded to treatment, improved the symptoms i.e heavy menstrual bleeding & pain, and showed a well-tolerated safety profile
- In the US, Relugolix and two hormonal therapies have been approved as Myfembree while Relugolix (GnRH antagonist) is also available as Orgovyx for prostate cancer
Ref: Pharmaphorum | Image: Gedeon Richter
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
